Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVO crawled time : 10:00 save search
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Published: 2024-03-25 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.19%
H: 0.97%
C: 0.04%
disease pipeline pharmaceuticals acquire cardiovascular
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
Global Diet Pills Market Research Report 2023: Market is Expected to Reach $ 2.47 Billion in 2027 - Focus on Xenical, Qsymia, Saxenda, Diethylpropion, Liraglutide, and Phentermine
Published: 2023-10-05 (Crawled : 10:00) - prnewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.08%
H: 1.44%
C: 1.15%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: -0.39%
H: 0.72%
C: 0.61%
report expected reach research global market
Semaglutide 2.4 mg shows large reductions in heart failure-related symptoms and physical limitations in people with heart failure with preserved ejection fraction and obesity
Published: 2023-08-25 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.34%
H: 1.29%
C: 0.93%
obesity heart
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
Published: 2023-08-10 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -1.44%
H: 0.99%
C: -1.51%
metabolic pharma acquire diabetes living
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Published: 2023-08-08 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 15.34%
H: 3.26%
C: 1.64%
obesity risk trial cardiovascular
Novo Nordisk A/S – Share repurchase programme
Published: 2023-06-06 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 2.4%
H: 0.25%
C: -0.54%
repurchase
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Published: 2023-05-24 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.59%
H: 0.25%
C: -0.45%
rare life collaboration therapeutics
Non-Alcoholic Steatohepatitis Biomarkers Market Booming: Projected Market Value of US$ 8177.9 billion and CAGR of 31.3%
Published: 2023-05-18 (Crawled : 10:00) - prnewswire.com
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -0.11%
H: 0.19%
C: -0.63%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.44%
H: 0.51%
C: 0.43%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: -0.49%
H: 0.42%
C: -0.37%
biomarkers market
Correction: Zealand Pharma Announces Full Year Results for 2022
Published: 2023-03-02 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.53%
H: 1.28%
C: 1.06%
pharma year
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023
Published: 2023-02-21 (Crawled : 10:00) - biospace.com/
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.55%
H: 0.77%
C: 0.14%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: -3.76%
H: 0.0%
C: -0.65%
pharma
Innate Pharma to Participate in Upcoming Investor Conferences - February 07, 2023
Published: 2023-02-07 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.19%
H: 1.01%
C: 0.91%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.64%
H: 0.0%
C: 0.0%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: -0.74%
H: 2.52%
C: 1.33%
pharma
Clinical Trials Market to be Worth $78.3 Billion by 2030: Million Insights
Published: 2022-11-23 (Crawled : 10:00) - prnewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 1.65%
H: 0.51%
C: 0.47%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.13%
H: 0.31%
C: 0.11%
ICLR | $288.625 -1.1% 73K
|
Health Technology
|
| O: 0.01%
H: 1.09%
C: 0.35%
trials market
Insulin Market is Likely to Upsurge USD 25.12 Billion Globally by 2029, Size, Share, Trends, Demand, Market Dynamics, Growth Forecast and Challenges
Published: 2022-11-07 (Crawled : 10:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -2.01%
H: 0.88%
C: 0.88%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.91%
H: 1.82%
C: 1.43%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.17%
H: 2.51%
C: 1.97%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
insulin growth market
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Published: 2022-11-04 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.25%
H: 0.11%
C: -1.03%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: -4.27%
H: 8.9%
C: 6.93%
pharma trial results platform
Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis
Published: 2022-10-11 (Crawled : 10:00) - prnewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.25%
H: 1.95%
C: 0.77%
pharma seeds positive
Novo Nordisk A/S – Share repurchase programme
Published: 2022-08-03 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -2.42%
H: 0.15%
C: -12.28%
repurchase
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
Published: 2022-08-01 (Crawled : 10:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -14.87%
H: 4.09%
C: 4.09%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -3.9%
H: 0.0%
C: 0.0%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.21%
H: 0.41%
C: -0.73%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: -11.25%
H: 0.0%
C: -1.06%
AZN | $68.545 0.27% 1.2M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
pharma update study
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2022-05-06 (Crawled : 10:00) - globenewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -1.88%
H: 1.63%
C: 0.56%
Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020
Published: 2022-03-28 (Crawled : 10:00) - prnewswire.com
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 0.14%
H: 1.23%
C: 1.17%
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.